Vericel [VCEL] vs Vertex [VRTX] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Vericel wins in 5 metrics, Vertex wins in 13 metrics, with 0 ties. Vertex appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricVericelVertexBetter
P/E Ratio (TTM)231.7128.68Vertex
Price-to-Book Ratio5.336.02Vericel
Debt-to-Equity Ratio32.748.89Vertex
PEG Ratio-2.57-0.22Vericel
EV/EBITDA170.4320.53Vertex
Profit Margin (TTM)2.85%31.86%Vertex
Operating Margin (TTM)-3.21%38.93%Vertex
EBITDA Margin (TTM)N/A38.93%N/A
Return on Equity2.59%22.77%Vertex
Return on Assets (TTM)0.18%13.09%Vertex
Free Cash Flow (TTM)$-5.81M$-978.00MVericel
1-Year Return-25.18%-11.42%Vertex
Price-to-Sales Ratio (TTM)6.579.06Vericel
Enterprise Value$1.62B$98.55BVertex
EV/Revenue Ratio6.518.63Vericel
Gross Profit Margin (TTM)73.71%86.25%Vertex
Revenue per Share (TTM)$5$44Vertex
Earnings per Share (Diluted)$0.14$14.06Vertex
Beta (Stock Volatility)1.390.43Vertex
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Vericel vs Vertex Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Vericel4.01%7.31%-3.31%-22.28%-25.41%-41.14%
Vertex-0.10%4.55%1.68%-12.25%-16.68%-0.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Vericel-25.18%38.10%48.67%1,187.30%0.75%-90.78%
Vertex-11.42%36.61%49.40%266.64%1,042.17%1,773.20%

News Based Sentiment: Vericel vs Vertex

Vericel

News based Sentiment: POSITIVE

October saw a notable increase in institutional investment in Vericel, alongside generally positive analyst sentiment and solid Q2 earnings. While some profit-taking occurred, the overall trend suggests continued confidence in the company's growth potential, making it a noteworthy month for investors.

View Vericel News Sentiment Analysis

Vertex

News based Sentiment: MIXED

October presented a mixed bag for Vertex, with a major FDA approval and positive financial results offset by a failed clinical trial and increased operating expenses. The strategic pipeline advancements and strong financial position suggest continued growth potential, but investors should monitor the impact of the trial setback and expense increases.

View Vertex News Sentiment Analysis

Performance & Financial Health Analysis: Vericel vs Vertex

MetricVCELVRTX
Market Information
Market Cap i$1.66B$103.40B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i701,6301,835,420
90 Day Avg. Volume i842,0271,652,450
Last Close$33.74$402.90
52 Week Range$29.24 - $63.00$362.50 - $519.88
% from 52W High-46.44%-22.50%
All-Time High$1,590.00 (Sep 22, 1997)$519.88 (Nov 04, 2024)
% from All-Time High-97.88%-22.50%
Growth Metrics
Quarterly Revenue Growth0.20%0.12%
Quarterly Earnings Growth0.20%0.12%
Financial Health
Profit Margin (TTM) i0.03%0.32%
Operating Margin (TTM) i-0.03%0.39%
Return on Equity (TTM) i0.03%0.23%
Debt to Equity (MRQ) i32.748.89
Cash & Liquidity
Book Value per Share (MRQ)$6.08$67.02
Cash per Share (MRQ)$2.32$24.90
Operating Cash Flow (TTM) i$47.24M$3.85B
Levered Free Cash Flow (TTM) i$-5,594,625$2.91B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Vericel vs Vertex

MetricVCELVRTX
Price Ratios
P/E Ratio (TTM) i231.7128.68
Forward P/E i67.5821.49
PEG Ratio i-2.57-0.22
Price to Sales (TTM) i6.579.06
Price to Book (MRQ) i5.336.02
Market Capitalization
Market Capitalization i$1.66B$103.40B
Enterprise Value i$1.62B$98.55B
Enterprise Value Metrics
Enterprise to Revenue i6.518.63
Enterprise to EBITDA i170.4320.53
Risk & Other Metrics
Beta i1.390.43
Book Value per Share (MRQ) i$6.08$67.02

Financial Statements Comparison: Vericel vs Vertex

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)VCELVRTX
Revenue/Sales i$52.60M$2.96B
Cost of Goods Sold i$16.33M$407.50M
Gross Profit i$36.27M$2.56B
Research & Development i$7.26M$978.40M
Operating Income (EBIT) i$-12.79M$1.15B
EBITDA i$-8.41M$1.34B
Pre-Tax Income i$-11.25M$1.28B
Income Tax iN/A$250.10M
Net Income (Profit) i$-11.25M$1.03B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)VCELVRTX
Cash & Equivalents i$73.49M$4.67B
Total Current Assets i$197.64M$10.01B
Total Current Liabilities i$39.45M$3.78B
Long-Term Debt i$87.80M$1.65B
Total Shareholders Equity i$295.49M$16.50B
Retained Earnings i$-404.06M$10.25B
Property, Plant & Equipment i$68.72M$2.63B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)VCELVRTX
Operating Cash Flow i$12.44M$404.90M
Capital Expenditures iN/A$-40.70M
Free Cash Flow i$-7.61M$778.20M
Debt Repayment iN/A$-1.30M
Common Stock Repurchase iN/A$-696.60M

Short Interest & Institutional Ownership Analysis

MetricVCELVRTX
Shares Short i4.75M4.05M
Short Ratio i6.532.83
Short % of Float i0.12%0.02%
Average Daily Volume (10 Day) i701,6301,835,420
Average Daily Volume (90 Day) i842,0271,652,450
Shares Outstanding i49.63M256.94M
Float Shares i49.90M255.58M
% Held by Insiders i0.01%0.00%
% Held by Institutions i1.13%0.98%

Dividend Analysis & Yield Comparison: Vericel vs Vertex

MetricVCELVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A